ZA201101938B - Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment - Google Patents

Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Info

Publication number
ZA201101938B
ZA201101938B ZA2011/01938A ZA201101938A ZA201101938B ZA 201101938 B ZA201101938 B ZA 201101938B ZA 2011/01938 A ZA2011/01938 A ZA 2011/01938A ZA 201101938 A ZA201101938 A ZA 201101938A ZA 201101938 B ZA201101938 B ZA 201101938B
Authority
ZA
South Africa
Prior art keywords
fgfr
inhibitors
treatment
methods
growth factor
Prior art date
Application number
ZA2011/01938A
Other languages
English (en)
Inventor
Haijun Sun
Ling Liu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of ZA201101938B publication Critical patent/ZA201101938B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/01938A 2008-10-20 2011-03-14 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment ZA201101938B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
ZA201101938B true ZA201101938B (en) 2012-08-29

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/01938A ZA201101938B (en) 2008-10-20 2011-03-14 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Country Status (17)

Country Link
US (3) US8043618B2 (https=)
EP (1) EP2342232A2 (https=)
JP (1) JP5577345B2 (https=)
KR (1) KR101370798B1 (https=)
CN (2) CN103524620A (https=)
AR (1) AR073770A1 (https=)
AU (1) AU2009307841B2 (https=)
BR (1) BRPI0919832A8 (https=)
CA (1) CA2741127C (https=)
EA (1) EA021584B1 (https=)
IL (1) IL211807A0 (https=)
MX (1) MX2011004317A (https=)
NZ (1) NZ592369A (https=)
TW (1) TWI381848B (https=)
UA (1) UA101681C2 (https=)
WO (1) WO2010048026A2 (https=)
ZA (1) ZA201101938B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
TWI507205B (zh) 2009-03-25 2015-11-11 Genentech Inc 抗ｆｇｆｒ３抗體及使用方法
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
CA2943355C (en) 2014-03-25 2023-09-05 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
US9817093B2 (en) * 2014-09-05 2017-11-14 Hyperfine Research, Inc. Low field magnetic resonance imaging methods and apparatus
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
JP6774421B2 (ja) * 2015-02-19 2020-10-21 フュージョン ファーマシューティカルズ インク． がんの治療のための方法、組成物、及びキット
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
PT3481859T (pt) 2016-07-07 2022-05-23 Pfizer Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos
WO2018129451A2 (en) * 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
IL300623A (en) 2020-08-21 2023-04-01 Genzyme Corp Anti-FGFR3 antibodies and methods of use
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
AU2023379457A1 (en) * 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2550245A1 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
JP5161882B2 (ja) * 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
US8012474B2 (en) * 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden

Also Published As

Publication number Publication date
TWI381848B (zh) 2013-01-11
CA2741127A1 (en) 2010-04-29
EA201170590A1 (ru) 2011-10-31
US8182815B2 (en) 2012-05-22
CN102186884A (zh) 2011-09-14
US20120219563A1 (en) 2012-08-30
KR101370798B1 (ko) 2014-03-14
US8043618B2 (en) 2011-10-25
CA2741127C (en) 2015-06-02
US20120009200A1 (en) 2012-01-12
EP2342232A2 (en) 2011-07-13
CN102186884B (zh) 2014-08-13
AU2009307841B2 (en) 2013-09-12
CN103524620A (zh) 2014-01-22
JP2012505912A (ja) 2012-03-08
BRPI0919832A2 (pt) 2015-12-15
UA101681C2 (ru) 2013-04-25
BRPI0919832A8 (pt) 2019-01-08
TW201026325A (en) 2010-07-16
NZ592369A (en) 2013-02-22
WO2010048026A3 (en) 2010-07-15
MX2011004317A (es) 2011-06-24
AU2009307841A1 (en) 2010-04-29
JP5577345B2 (ja) 2014-08-20
WO2010048026A2 (en) 2010-04-29
KR20110056554A (ko) 2011-05-30
IL211807A0 (en) 2011-06-30
US8404240B2 (en) 2013-03-26
EA021584B1 (ru) 2015-07-30
US20100098696A1 (en) 2010-04-22
AR073770A1 (es) 2010-12-01

Similar Documents

Publication Publication Date Title
ZA201101938B (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
ZA201103759B (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP2352452A4 (en) SYSTEMS AND METHOD FOR TREATING PROSTATE TISSUE
SMT201800248T1 (it) Sistemi e metodi per il trattamento di tessuto prostatico
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
IL194820A0 (en) Devices and methods for treatment of tissue
ZA201100211B (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
SI2379096T1 (sl) Zaviralci TFPI in postopki uporabe
EP2170180A4 (en) METHOD AND DEVICES FOR TREATING VESSELS AND PROSTATE
IL212079A0 (en) Methods and devices for treating sleep apnea
GB0821927D0 (en) Article and method of surface treatment of an article
EP2136847A4 (en) OLIGORIBONUCLEOTIDE HEMMER OF NRF2 AND METHOD OF USE THEREOF FOR THE TREATMENT OF CANCER
IL207132A0 (en) Composition and method for seed treatment use
HUE036609T2 (hu) Eljárás és készítmények rák kezelésére
EP2493550A4 (en) ELECTRO-OPTICAL FABRIC STIMULATOR AND METHOD OF USE THEREOF
IL220147A0 (en) Inhibitors of vascular endothelial growth factor (vegf) receptro and methods of use thereof
EP2303160A4 (en) BONE FRACTURE TREATMENT DEVICES AND METHODS OF USE
PL3034472T3 (pl) Sposób oczyszczania i aparatura do oczyszczania ścieku
EP2376083A4 (en) QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
GB2463474B (en) Therapeutic bone growth and regeneration
WO2009151620A9 (en) Pain treatment using erk2 inhibitors
HK1156641A (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment